Also, predicated on baseline HBsAg levels, cumulative relapse prices at 4 years were higher for those with degrees of at least 2000 IU/mL significantly, at 62.8 percent compared with 33.7 percent for those with lower amounts. Despite previous evidence showing that prolonged consolidation therapy greater than 18 or 24 months protects against HBV relapse, there was no proof this in today’s study. And there was no factor in post-treatment HBV relapse rates between individuals taking entecavir and those taking lamivudine. Licensed from medwireNews with authorization from Springer Healthcare Ltd.Conversation of the experimental treatments with the prespecified subgroups was assessed by fitting a Cox model with one term representing the treatment group, one representing the covariate of curiosity, and an interaction term. The following subgroups were considered: pharmacologic versus nonpharmacologic cytoreductive therapy; sex; median age; previous thrombosis versus no previous thrombosis; low-risk disease versus high-risk disease; baseline platelet and white-cell counts ; the presence or lack of splenomegaly, diabetes, or hypertension; and the use versus nonuse of aspirin or other anticoagulant drugs.